Targeted Therapies

Oral Targeted Therapies

• STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors

Antibody Drug Conjugate (ADC)

• Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

• BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors

• ZL-1310 in Participants With Selected Solid Tumors

DLL-3

• DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers

• DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers

• DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC)

• Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms